Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
JCO Global Oncology · 2023-02 · (9)
DOI: 10.1200/go.22.00246 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Global Oncology, 2023-02. Verfasst von Dharna Gupta und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE Tyrosine kinase inhibitors such as sunitinib and pazopanib are the mainstay of treatment of metastatic renal cell carcinoma (mRCC) in India. However, pembrolizumab and nivolumab have shown significant improvement in the median progression-free survival and overall survival among patients with mRCC. In this study, we aimed to determine the cost-effectiveness of the first-line treatment options for the patients with mRCC in India. METHODS A Markov state-transition model was used to measure the lifetime costs and health outcomes associated with sunitinib, pazopanib, pembrolizumab/lenvatinib, and nivolumab/ipilimumab among patients with first-line mRCC. Incremental cost per quality-adjusted life-year (QALY) gained with a given treatment option was compared against the next best alternative and assessed for cost-effectiveness using a willingness to pay threshold of one-time per capita gross-domestic product of India. The parameter uncertainty was analyzed using the probabilistic sensitivity analysis. RESULTS We estimated the total lifetime cost per patient of ₹ 0.27 million ($3,706 US dollars [USD]), ₹ 0.35 million ($4,716 USD), ₹ 9.7 million ($131,858 USD), and ₹ 6.7 million ($90,481 USD) for the sunitinib, pazopanib, pembrolizumab/lenvatinib, and nivolumab/ipilimumab arms, respectively. Similarly, the mean QALYs lived per patient were 1.91, 1.86, 2.75, and 1.97, respectively. Sunitinib incurs an average cost of ₹ 143,269 ($1,939 USD) per QALY lived. Therefore, sunitinib at current reimbursement rates (₹ 10,000 per cycle) has a 94.6% probability of being cost-effective at a willingness to pay threshold of 1-time per capita gross-domestic product (₹ 168,300) in the Indian context. CONCLUSION Our findings support the current inclusion of sunitinib under India's publicly financed health insurance scheme.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Community Medicine and School of Public Health, Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.
- Department of Medical Oncology, Christian Medical College, Vellore, Tamil Nadu, India.
- Department of Radiation Oncology, Government Medical College and Hospital, Chandigarh, India.
- Department of Medical Oncology, Adyar Cancer Institute, Chennai, Tamil Nadu, India.
- School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.
- National Health Authority, Ayushman Bharat PM-JAY, Government of India, New Delhi, India.
ORCID-Profile: Ashish Singh, Nidhi Gupta, Nikita Mehra, Pankaj Bahuguna, Manjunath Nookala Krishnamurthy, Pankaj Malhotra, Sudeep Gupta, Lalit Kumar, Shankar Prinja
Zitieren
APA
Gupta, D., Singh, A., Gupta, N., Mehra, N., Bahuguna, P., Aggarwal, V., Krishnamurthy, M. N., Roy, P. S., Malhotra, P., Gupta, S., Kumar, L., Kataki, A., & Prinja, S. (2023). Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India. JCO Global Oncology. https://doi.org/10.1200/go.22.00246
Vancouver
Gupta D, Singh A, Gupta N, Mehra N, Bahuguna P, Aggarwal V, et al. Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India. JCO Global Oncology. 2023. doi:10.1200/go.22.00246
BibTeX
@article{Gupta2023,
author = {Gupta, Dharna and Singh, Ashish and Gupta, Nidhi and Mehra, Nikita and Bahuguna, Pankaj and Aggarwal, Vipul and Krishnamurthy, Manjunath Nookala and Roy, Partha Sarathi and Malhotra, Pankaj and Gupta, Sudeep and Kumar, Lalit and Kataki, Amal and Prinja, Shankar},
title = {Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India},
journal = {JCO Global Oncology},
year = {2023},
number = {9},
doi = {10.1200/go.22.00246}
}
EUVIMED